Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?

Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion JP.

Chem Sci. 2019 Jul 18;10(35):8119-8128. doi: 10.1039/c9sc02290b. eCollection 2019 Sep 21.

2.

Targeted Gold Nanocluster-Enhanced Radiotherapy of Prostate Cancer.

Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion JP.

Small. 2019 Aug;15(34):e1900968. doi: 10.1002/smll.201900968. Epub 2019 Jul 2.

PMID:
31265213
3.

Molecular imaging and validation of margins in surgically excised nonmelanoma skin cancer specimens.

Liu Y, Walker E, Iyer SR, Biro M, Kim I, Zhou B, Straight B, Bogyo M, Basilion JP, Popkin DL, Wilson DL.

J Med Imaging (Bellingham). 2019 Jan;6(1):016001. doi: 10.1117/1.JMI.6.1.016001. Epub 2019 Mar 18.

PMID:
30915384
4.

Sink or float? Characterization of shell-stabilized bulk nanobubbles using a resonant mass measurement technique.

Hernandez C, Abenojar EC, Hadley J, de Leon AC, Coyne R, Perera R, Gopalakrishnan R, Basilion JP, Kolios MC, Exner AA.

Nanoscale. 2019 Jan 17;11(3):851-855. doi: 10.1039/c8nr08763f.

5.

Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.

Mangadlao JD, Wang X, McCleese C, Escamilla M, Ramamurthy G, Wang Z, Govande M, Basilion JP, Burda C.

ACS Nano. 2018 Apr 24;12(4):3714-3725. doi: 10.1021/acsnano.8b00940. Epub 2018 Apr 16.

6.

Synthesis and evaluation of MR probes for targeted-reporter imaging.

Verma KD, Massing JO, Kamper SG, Carney CE, MacRenaris KW, Basilion JP, Meade TJ.

Chem Sci. 2017 Aug 1;8(8):5764-5768. doi: 10.1039/c7sc02217d. Epub 2017 Jun 13.

7.

Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection.

Tummers WS, Warram JM, Tipirneni KE, Fengler J, Jacobs P, Shankar L, Henderson L, Ballard B, Pfefer TJ, Pogue BW, Weichert JP, Bouvet M, Sorger J, Contag CH, Frangioni JV, Tweedle MF, Basilion JP, Gambhir SS, Rosenthal EL.

Cancer Res. 2017 May 1;77(9):2197-2206. doi: 10.1158/0008-5472.CAN-16-3217. Epub 2017 Apr 20. Erratum in: Cancer Res. 2018 Feb 15;78(4):1123.

8.

Optical Surgical Navigation for Precision in Tumor Resections.

Harmsen S, Teraphongphom N, Tweedle MF, Basilion JP, Rosenthal EL.

Mol Imaging Biol. 2017 Jun;19(3):357-362. doi: 10.1007/s11307-017-1054-1. Review.

9.

Rapid visualization of nonmelanoma skin cancer.

Walker E, Mann M, Honda K, Vidimos A, Schluchter MD, Straight B, Bogyo M, Popkin D, Basilion JP.

J Am Acad Dermatol. 2017 Feb;76(2):209-216.e9. doi: 10.1016/j.jaad.2016.09.008. Epub 2016 Nov 19.

10.

Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.

Wang X, Tsui B, Ramamurthy G, Zhang P, Meyers J, Kenney ME, Kiechle J, Ponsky L, Basilion JP.

Mol Cancer Ther. 2016 Aug;15(8):1834-44. doi: 10.1158/1535-7163.MCT-15-0722. Epub 2016 Jun 13.

11.

Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts.

Herrmann K, Erokwu BO, Johansen ML, Basilion JP, Gulani V, Griswold MA, Flask CA, Brady-Kalnay SM.

Transl Oncol. 2016 Apr;9(2):147-154. doi: 10.1016/j.tranon.2016.02.004.

12.

Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report.

Rosenthal EL, Warram JM, de Boer E, Basilion JP, Biel MA, Bogyo M, Bouvet M, Brigman BE, Colson YL, DeMeester SR, Gurtner GC, Ishizawa T, Jacobs PM, Keereweer S, Liao JC, Nguyen QT, Olson JM, Paulsen KD, Rieves D, Sumer BD, Tweedle MF, Vahrmeijer AL, Weichert JP, Wilson BC, Zenn MR, Zinn KR, van Dam GM.

J Nucl Med. 2016 Jan;57(1):144-50. doi: 10.2967/jnumed.115.158915. Epub 2015 Oct 8.

13.

Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer.

Meyers JD, Cheng Y, Broome AM, Agnes RS, Schluchter MD, Margevicius S, Wang X, Kenney ME, Burda C, Basilion JP.

Part Part Syst Charact. 2015 Apr;32(4):448-457.

14.

Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Peiris PM, Abramowski A, Mcginnity J, Doolittle E, Toy R, Gopalakrishnan R, Shah S, Bauer L, Ghaghada KB, Hoimes C, Brady-Kalnay SM, Basilion JP, Griswold MA, Karathanasis E.

Cancer Res. 2015 Apr 1;75(7):1356-65. doi: 10.1158/0008-5472.CAN-14-1540. Epub 2015 Jan 27.

15.

Development of targeted near-infrared imaging agents for prostate cancer.

Wang X, Huang SS, Heston WD, Guo H, Wang BC, Basilion JP.

Mol Cancer Ther. 2014 Nov;13(11):2595-606. doi: 10.1158/1535-7163.MCT-14-0422. Epub 2014 Sep 19.

16.

Biocompatible nanoparticles of KGd(H₂O)₂[Fe(CN)₆]·H₂O with extremely high T₁-weighted relaxivity owing to two water molecules directly bound to the Gd(III) center.

Perera VS, Yang LD, Hao J, Chen G, Erokwu BO, Flask CA, Zavalij PY, Basilion JP, Huang SD.

Langmuir. 2014 Oct 14;30(40):12018-26. doi: 10.1021/la501985p. Epub 2014 Oct 3.

17.

Microscopic detection of quenched activity-based optical imaging probes using an antibody detection system: localizing protease activity.

Walker E, Gopalakrishnan R, Bogyo M, Basilion JP.

Mol Imaging Biol. 2014 Oct;16(5):608-18. doi: 10.1007/s11307-014-0736-1.

18.

On-command drug release from nanochains inhibits growth of breast tumors.

Peiris PM, Tam M, Vicente P, Abramowski A, Toy R, Bauer L, Mayer A, Pansky J, Doolittle E, Tucci S, Schmidt E, Shoup C, Rao S, Murray K, Gopalakrishnan R, Keri RA, Basilion JP, Griswold MA, Karathanasis E.

Pharm Res. 2014 Jun;31(6):1460-8. doi: 10.1007/s11095-013-1102-8. Epub 2013 Aug 9.

19.

Nanoparticles for imaging and treating brain cancer.

Meyers JD, Doane T, Burda C, Basilion JP.

Nanomedicine (Lond). 2013 Jan;8(1):123-43. doi: 10.2217/nnm.12.185. Review.

20.

Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu.

Burden-Gulley SM, Qutaish MQ, Sullivant KE, Tan M, Craig SE, Basilion JP, Lu ZR, Wilson DL, Brady-Kalnay SM.

Int J Cancer. 2013 Apr 1;132(7):1624-32. doi: 10.1002/ijc.27838. Epub 2012 Oct 11.

21.

An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor.

Agnes RS, Broome AM, Wang J, Verma A, Lavik K, Basilion JP.

Mol Cancer Ther. 2012 Oct;11(10):2202-11. doi: 10.1158/1535-7163.MCT-12-0211. Epub 2012 Jul 17.

22.

Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo.

Kaur H, Burden-Gulley SM, Phillips-Mason PJ, Basilion JP, Sloan AE, Brady-Kalnay SM.

Neuro Oncol. 2012 May;14(5):561-73. doi: 10.1093/neuonc/nos066. Epub 2012 Apr 14.

23.

Topical application of activity-based probes for visualization of brain tumor tissue.

Cutter JL, Cohen NT, Wang J, Sloan AE, Cohen AR, Panneerselvam A, Schluchter M, Blum G, Bogyo M, Basilion JP.

PLoS One. 2012;7(3):e33060. doi: 10.1371/journal.pone.0033060. Epub 2012 Mar 13.

24.

Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo.

Kaur H, Phillips-Mason PJ, Burden-Gulley SM, Kerstetter-Fogle AE, Basilion JP, Sloan AE, Brady-Kalnay SM.

Mol Cancer Res. 2012 Mar;10(3):293-304. doi: 10.1158/1541-7786.MCR-11-0457. Epub 2012 Jan 20.

25.

Cryo-image analysis of tumor cell migration, invasion, and dispersal in a mouse xenograft model of human glioblastoma multiforme.

Qutaish MQ, Sullivant KE, Burden-Gulley SM, Lu H, Roy D, Wang J, Basilion JP, Brady-Kalnay SM, Wilson DL.

Mol Imaging Biol. 2012 Oct;14(5):572-83. doi: 10.1007/s11307-011-0525-z.

26.

Novel cryo-imaging of the glioma tumor microenvironment reveals migration and dispersal pathways in vivid three-dimensional detail.

Burden-Gulley SM, Qutaish MQ, Sullivant KE, Lu H, Wang J, Craig SE, Basilion JP, Wilson DL, Brady-Kalnay SM.

Cancer Res. 2011 Sep 1;71(17):5932-40. doi: 10.1158/0008-5472.CAN-11-1553. Epub 2011 Aug 23.

27.

Nanoparticles of the novel coordination polymer KBi(H2O)2[Fe(CN)6]·H2O as a potential contrast agent for computed tomography.

Perera VS, Hao J, Gao M, Gough M, Zavalij PY, Flask C, Basilion JP, Huang SD.

Inorg Chem. 2011 Sep 5;50(17):7910-2. doi: 10.1021/ic200587s. Epub 2011 Jul 28.

PMID:
21797245
28.

Addressing brain tumors with targeted gold nanoparticles: a new gold standard for hydrophobic drug delivery?

Cheng Y, Meyers JD, Agnes RS, Doane TL, Kenney ME, Broome AM, Burda C, Basilion JP.

Small. 2011 Aug 22;7(16):2301-6. doi: 10.1002/smll.201100628. Epub 2011 Jun 1.

29.

Deep penetration of a PDT drug into tumors by noncovalent drug-gold nanoparticle conjugates.

Cheng Y, Meyers JD, Broome AM, Kenney ME, Basilion JP, Burda C.

J Am Chem Soc. 2011 Mar 2;133(8):2583-91. doi: 10.1021/ja108846h. Epub 2011 Feb 4.

30.

Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG 2nd, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W.

J Clin Invest. 2011 Jan;121(1):161-73. doi: 10.1172/JCI44798. Epub 2010 Dec 22.

31.

In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET).

Salem N, Balkman JD, Wang J, Wilson DL, Lee Z, King CL, Basilion JP.

PLoS Negl Trop Dis. 2010 Sep 21;4(9). pii: e827. doi: 10.1371/journal.pntd.0000827.

32.

A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu.

Burden-Gulley SM, Gates TJ, Burgoyne AM, Cutter JL, Lodowski DT, Robinson S, Sloan AE, Miller RH, Basilion JP, Brady-Kalnay SM.

Neoplasia. 2010 Apr;12(4):305-16.

33.

Expanding the utility of beta-galactosidase complementation: piece by piece.

Broome AM, Bhavsar N, Ramamurthy G, Newton G, Basilion JP.

Mol Pharm. 2010 Feb 1;7(1):60-74. doi: 10.1021/mp900188e.

34.

Nanoparticles for imaging, diagnosis, and therapeutics.

Labhasetwar V, Zborowski M, Abramson AR, Basilion JP.

Mol Pharm. 2009 Sep-Oct;6(5):1261-2. doi: 10.1021/mp9001798. No abstract available.

PMID:
19799461
35.

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen ML, Wang B.

Cancer Cell. 2009 Jul 7;16(1):9-20. doi: 10.1016/j.ccr.2009.04.009.

36.

Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers.

Hao J, Serohijos AW, Newton G, Tassone G, Wang Z, Sgroi DC, Dokholyan NV, Basilion JP.

PLoS Comput Biol. 2008 Aug 1;4(8):e1000138. doi: 10.1371/journal.pcbi.1000138.

37.

Magnetic resonance imaging: utility as a molecular imaging modality.

Basilion JP, Yeon S, Botnar R.

Curr Top Dev Biol. 2005;70:1-33. Review.

PMID:
16338335
38.
39.

Detection of peroxidase/H2O2-mediated oxidation with enhanced yellow fluorescent protein.

Tsourkas A, Newton G, Perez JM, Basilion JP, Weissleder R.

Anal Chem. 2005 May 1;77(9):2862-7.

PMID:
15859603
40.

[Molecular imaging of transgene expression in brain tumors].

Ichikawa T, Terada K, Tamiya T, Basilion JP, Chiocca EA, Date I.

No Shinkei Geka. 2004 Aug;32(8):805-24. Review. Japanese. No abstract available.

PMID:
15478648
41.

The transferrin receptor: a potential molecular imaging marker for human cancer.

Högemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP.

Neoplasia. 2003 Nov-Dec;5(6):495-506.

42.

PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli.

Abe T, Terada K, Wakimoto H, Inoue R, Tyminski E, Bookstein R, Basilion JP, Chiocca EA.

Cancer Res. 2003 May 1;63(9):2300-5.

43.

MRI of transgene expression: correlation to therapeutic gene expression.

Ichikawa T, Högemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, Chiocca EA, Basilion JP.

Neoplasia. 2002 Nov-Dec;4(6):523-30.

44.

"Seeing inside the body": MR imaging of gene expression.

Högemann D, Basilion JP.

Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):400-8. Review.

PMID:
12002717
45.

Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors.

Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, Basilion JP.

Cancer Gene Ther. 2002 Mar;9(3):228-35.

46.

Human transferrin receptor gene as a marker gene for MR imaging.

Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R.

Radiology. 2001 Oct;221(1):244-50.

PMID:
11568347
47.

Current and future technologies for breast cancer imaging.

Basilion JP.

Breast Cancer Res. 2001;3(1):14-6. Review. No abstract available.

48.

[Molecular imaging in magnetic resonance tomography and nuclear medicine].

Högemann D, Basilion JP, Weissleder R.

Radiologe. 2001 Feb;41(2):116-20. Review. German.

PMID:
11253096
49.

Improvement of MRI probes to allow efficient detection of gene expression.

Högemann D, Josephson L, Weissleder R, Basilion JP.

Bioconjug Chem. 2000 Nov-Dec;11(6):941-6.

PMID:
11087345
50.

In vivo magnetic resonance imaging of transgene expression.

Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP.

Nat Med. 2000 Mar;6(3):351-5. No abstract available.

PMID:
10700241

Supplemental Content

Loading ...
Support Center